Technical Analysis for ARWR - Arrowhead Research Corporation
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.35% | |
Stochastic Buy Signal | Bullish | -0.35% | |
Wide Bands | Range Expansion | -0.35% | |
Oversold Stochastic | Weakness | -0.35% | |
Wide Bands | Range Expansion | 2.73% | |
Oversold Stochastic | Weakness | 2.73% | |
NR7 | Range Contraction | 2.55% | |
Narrow Range Bar | Range Contraction | 2.55% |
Alert | Time |
---|---|
Up 1% | about 7 hours ago |
10 DMA Support | about 7 hours ago |
60 Minute Opening Range Breakout | about 7 hours ago |
Rose Above Previous Day's High | about 7 hours ago |
Down 2 % | about 9 hours ago |
Get a Trading Sidekick!
- Earnings date: 04/30/2024
Arrowhead Research Corporation Description
Arrowhead Research Corporation operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection. The company assembles a set of technologies, including Dynamic Polyconjugate platform, a RNA delivery system that addresses multiple organ systems and cell types, promotes multi-log gene knockdown in rodents and non-human primates, and induces endosomal escape; and RONDEL, a RNA delivery system for systemic siRNA delivery, and RNAi-mediated mRNA and protein knockdown in human melanoma patients. It also offers Homing Peptides platform, a library of short peptides for the development of peptide-drug conjugates and companion diagnostics. The company's principal product candidates include Adipotide, an anti-obesity peptide, which is in Phase I clinical trial for disrupting the blood supply that supports unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue; ARC-520, an RNAi-based therapeutic to treat chronic HBV infection; and CALAA-01, an RNAi-based therapeutic that has completed a Phase IB clinical trial, which targets solid tumors. Its products also comprise CRLX-101 for NSC lung cancer; and Tubulin Inhibitor for oncology. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Organ Systems Molecular Biology Infection Obesity Hepatitis B Gene Expression RNA Rna Interference Apoptosis Chronic Hepatitis B Virus Chronic Hbv Infection Rna Therapeutics Si RNA Small Interfering Rna
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 42.48 |
52 Week Low | 20.67 |
Average Volume | 1,369,990 |
200-Day Moving Average | 30.09 |
50-Day Moving Average | 31.16 |
20-Day Moving Average | 30.11 |
10-Day Moving Average | 28.08 |
Average True Range | 1.61 |
RSI (14) | 44.75 |
ADX | 19.21 |
+DI | 20.39 |
-DI | 23.00 |
Chandelier Exit (Long, 3 ATRs) | 31.90 |
Chandelier Exit (Short, 3 ATRs) | 31.82 |
Upper Bollinger Bands | 36.11 |
Lower Bollinger Band | 24.10 |
Percent B (%b) | 0.37 |
BandWidth | 39.90 |
MACD Line | -1.02 |
MACD Signal Line | -0.98 |
MACD Histogram | -0.0386 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 30.16 | ||||
Resistance 3 (R3) | 30.15 | 29.61 | 29.90 | ||
Resistance 2 (R2) | 29.61 | 29.22 | 29.62 | 29.81 | |
Resistance 1 (R1) | 29.11 | 28.97 | 28.84 | 29.12 | 29.73 |
Pivot Point | 28.57 | 28.57 | 28.44 | 28.58 | 28.57 |
Support 1 (S1) | 28.07 | 28.18 | 27.80 | 28.08 | 27.47 |
Support 2 (S2) | 27.53 | 27.93 | 27.54 | 27.39 | |
Support 3 (S3) | 27.03 | 27.53 | 27.30 | ||
Support 4 (S4) | 27.04 |